This study establishes RACGAP1 as a novel, potent target for therapeutic intervention and necessitates further experimental and clinical evaluations to explore RACGAP1 inhibitors or modulators to improve ovarian cancer treatment strategies [76]. Here, RACGAP1 is linked to ovarian cancer.